Aridis Pharmaceuticals Stock (OTC:ARDS), Trade Ideas

Aridis Pharmaceuticals

Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ABOS

ADES

APLS

APVO

ARDS

ATRO

ATUS

AWIN

BPTS

EOSE

Euda Health Holdings Limited - Ordinary Shares

EUDA

EXPI

FREY

FWBI

GRRR

HCTI

HYPR

ICAD

INOD

IRNT

ISUN

LINK

LIXT

MASI

MBWM

MICS

MNMD

NMTR

NOVN

PACW

PIRS

QBTS

RVYL

SCHW

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

SNAX

UTME

Gainers


	Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) gained 90% to $0.3560 after the company issued strategic update and announced restructuring.


Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Biotech

Health Care

Pre-Market Outlook

General

Aridis Pharmaceuticals Inc (NASDAQ: ARDS) shares are gaining after announcing positive European Medicines Agency feedback on its proposed single confirmatory Phase 3 study of investigational monoclonal 

Why Are Aridis Pharmaceuticals Shares Moving Higher Today?

HKIT

KPTI

TAOP

TCBP

VAPO

Gainers


	Biophytis S.A. (NASDAQ: BPTS) shares surged 53.9% to $3.31 in pre-market trading after the company signed a partnership with SEQENS to produce Sarconeos (BIO101) active compound, the company&#39;s main product.


Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket

ARIDIS PHARMACEUTICAL INC by Aridis Pharmaceuticals Inc.

Aridis Pharmaceuticals Inc

ACM Research Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACMR#NASDAQ">ACMR</a>) shares are trading lower on Friday after the company announced preliminary unaudited&nbsp;<a href="https://www.benzinga.com/pressreleases/24/04/g38454367/acm-research-announces-preliminary-unaudited-revenue-and-shipments-for-the-first-quarter-2024" target="_blank" rel="noreferrer noopener">revenue and shipments for the first quarter.</a>
The company registered preliminary unaudited revenue for the first quarter of 2024 of $150 million to $152 million versus&nbsp;the estimate&nbsp;of $152.41 million.&nbsp;This&nbsp;represents&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">year-over-year growth of 102% to 105%</a>.
The company said preliminary total shipments&nbsp;are expected&nbsp;to be&nbsp;in the range of&nbsp;$235 million to $240 million,&nbsp;which would represent&nbsp;year-to-year growth of 163% to 169%.
ACM Research&nbsp;reaffirmed&nbsp;full year&nbsp;2024 revenue outlook in the range of $650 million to $725 million versus $701.7 million,&nbsp;which would&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">represent&nbsp;year-to-year growth of 17% to 30%.</a>
According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>, ACM Research stock has gained over 117% in the past year. Investors can gain exposure to the stock via Invesco Semiconductors ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSI#NYSE">PSI</a>) and Matthews China Discovery Active ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHS#NASDAQ">MCHS</a>).
ACMR Price Action:&nbsp;ACM Research shares are trading lower by 4.28% to $27.08 at publication Friday.&nbsp;
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38465570/snap-investors-celebrate-q1-earnings-but-analysts-arent-ready-to-party-just-yet-the">Snap Investors Celebrate Q1 Earnings, But Analysts Aren&#8217;t Ready To Party Just Yet: &#8216;The Most Expensive Name In Social&#8217;</a>

Equities

ACMR

MCHS

PowerShares Exchange-Traded Fund Trust Dynamic Semiconductor Portfolio

Why ACM Research Shares Are Falling Today

AERWINS Technologies Shares Halted On Circuit Breaker To The Upside, Stock Now Up 73.4%

Evercore ISI Group maintains Patterson Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) with a In-Line and lowers the price target from $28 to $27.

Price Target

Analyst Ratings

PDCO

Evercore ISI Group Maintains In-Line on Patterson Cos, Lowers Price Target to $27

Wedbush analyst Nick Setyan maintains Wingstop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) with a Outperform and raises the price target from $340 to $400.

WING

Wedbush Maintains Outperform on Wingstop, Raises Price Target to $400

Peoples Bancorp of NC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEBK#NASDAQ">PEBK</a>) reported quarterly earnings of $0.72 per share. This is a 28.57 percent increase over earnings of $0.56 per share from the same period last year. The company reported $19.34 million in sales this quarter. This is a 7.76 percent increase over sales of $17.95 million the same period last year.

Earnings

PEBK

Peoples Bancorp of NC Q1 EPS $0.72 Up From $0.56 YoY, Sales $19.34M Up From $17.95M YoY

Evercore ISI Group analyst Greg Melich maintains O'Reilly Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>) with a Outperform and lowers the price target from $1220 to $1200.

ORLY

Evercore ISI Group Maintains Outperform on O'Reilly Automotive, Lowers Price Target to $1200

Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares are trading higher Friday. Several AI-related and chip stocks are rising following better-than-expected earnings from Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38441148/metas-q1-earnings-analysts-say-support-its-ai-strategy-use-meta-as-a-source-of-fund">increased its capex outlook.&nbsp;</a>
The Details:
Microsoft delivered better-than-expected first-quarter results Thursday, and Microsoft CEO Satya Nadella highlighted <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38465071/microsoft-q3-shines-light-on-ai-innovation-cycle-analysts-see-plenty-of-runway-for-">strong demand </a>for the company's offerings, particularly in the field of artificial intelligence (AI).
Meta also reported strong first-quarter results this week and raised its capital expenditures outlook amid the company's increased efforts in AI.
Wedbush analyst Dan Ives expressed his <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38463199/dan-ives-says-ai-is-the-fourth-industrial-revolution-after-robust-results-from-micr">excitement </a>about the strong results from Microsoft and Alphabet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and emphasized the need for increased AI spending, as companies shift towards the "fourth industrial revolution."
Nvidia shares have gained nearly 15% over the past five days after dropping 10% last Friday in the stock's largest one-day loss since 2020.&nbsp;
Related News: <a href="https://www.benzinga.com/news/earnings/24/04/38445632/snap-shares-soar-on-better-than-expected-q1-results-daily-active-user-growth-q2-revenue-guidance">Snap Shares Soar On Better-Than-Expected Q1 Results, Daily Active User Growth, Q2 Revenue Guidance</a>
<h2 class="wp-block-heading">Should I Sell My NVDA Stock? </h2>
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
Shares of Nvidia have gained 214.76% year to date. This compares to the average annual return of 74.89%, meaning the stock has outperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity. 
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Nvidia stock currently has an RSI of 46.67, indicating neutral conditions.
For analysis tools, charting data and access to exclusive stock news, check out <a href='https://pro.benzinga.com/'>Benzinga PRO. Try it for free.</a> 
NVDA Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Nvidia shares are up 5.91% at $875.16 at the time of publication Friday.
Image: Shutterstock

GOOG

GOOGL

MSFT

NVDA

What's Going On With Nvidia's Stock?

Evercore ISI Group analyst Ross Muken maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Outperform and lowers the price target from $350 to $330.

ICLR

Evercore ISI Group Maintains Outperform on Icon, Lowers Price Target to $330

WIIM

MOG/A

Moog shares are trading lower after the company reported worse-than-expected Q2 financial results and raised its FY24 guidance above estimates.

Evercore ISI Group analyst Jonathan Chappell maintains Hub Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUBG#NASDAQ">HUBG</a>) with a Outperform and lowers the price target from $46 to $44.

HUBG

Evercore ISI Group Maintains Outperform on Hub Group, Lowers Price Target to $44

Phillips 66 Expects Gasoline, Diesel Demand To Remain Flat In 2024

Macro Economic Events

Econ #s

Economics

U.S. Baker Hughes Oil Rig Count -5; U.S. Baker Hughes Gas Rig Count -1; U.S. Baker Hughes Total Rig Count 613 Vs 619 Prior

Trump Media & Technology Group shares are trading higher as the stock continues to experience volatility.

Wedbush analyst Nick Setyan maintains Wendy's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>) with a Neutral and raises the price target from $19 to $20.

Wedbush Maintains Neutral on Wendy's, Raises Price Target to $20

Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares are trading higher Friday as AI and chip stocks gain following <a href="https://www.benzinga.com/news/earnings/24/04/38444199/microsoft-q3-earnings-revenue-beat-eps-beat-new-era-of-ai-transformation-and-more">Microsoft Corporation's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) earnings.</a>
The Details:
Microsoft delivered better-than-expected earnings after the bell Thursday. Microsoft CEO Satya Nadella highlighted <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38465071/microsoft-q3-shines-light-on-ai-innovation-cycle-analysts-see-plenty-of-runway-for-">strong demand </a>for the company's offerings, particularly in the field of artificial intelligence (AI).
SMCI shares also rose Thursday after Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) reported its <a href="https://www.benzinga.com/news/earnings/24/04/38430266/meta-platforms-stock-is-tumbling-thursday-whats-going-on">first-quarter</a> results and increased its capital expenditures outlook amid the company's AI efforts.
SMCI is set to report its third-quarter financial results after the bell on April 30 and will host a conference call to discuss the results at 5:00 p.m. ET the same day. According to estimates from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, analysts expect the company to report earnings of $5.84 per share and quarterly revenue of $3.99 billion.&nbsp;
The company has beat analysts expectations for the last three reported quarters.&nbsp;
Related News: <a href="https://www.benzinga.com/news/earnings/24/04/38445632/snap-shares-soar-on-better-than-expected-q1-results-daily-active-user-growth-q2-revenue-guidance">Snap Shares Soar On Better-Than-Expected Q1 Results, Daily Active User Growth, Q2 Revenue Guidance</a>
<h2 class="wp-block-heading">SMCI Stock Prediction 2024: </h2>
Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.
Shares of Super Micro Computer have an average 1-year price target of $961.13, representing an expected upside of 14.51%.
Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. 1 analyst has a bearish recommendation on Super Micro Computer, while 10 analysts have bullish ratings. The street high price target from Loop Capital is $1500, while the street low from Susquehanna is $250.
SMCI Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Super Micro Computer shares are up 7.46% at $846.17 at the time of publication Friday.
Image: Courtesy of Super Micro Computer, Inc.

SMCI

What's Going On With Super Micro Computer Stock?

Wedbush analyst Nick Setyan maintains Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Neutral and lowers the price target from $95 to $92.

SBUX

Wedbush Maintains Neutral on Starbucks, Lowers Price Target to $92

Evercore ISI Group analyst Vijay Kumar maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a In-Line and lowers the price target from $92 to $89.

Evercore ISI Group Maintains In-Line on Edwards Lifesciences, Lowers Price Target to $89

California's solar energy efforts have been so successful that renewable energy has powered 100% of the state's main grid for at least 15 minutes on most days over the past month.
But now, the state and its grid operator are facing an unusual situation. With an abundance of solar energy integrated into the grid, during bright spring days with reduced demand, electricity prices plummet into negative territory. The surplus of solar power results in gigawatts being "curtailed" or effectively wasted, according to a report in The Washington Post.
California's response to balancing renewable energy goals with rooftop solar economics has been to reduce incentives and slow installations. This approach, while addressing short-term grid issues, might hinder long-term solar development in the state. As other states ramp up solar capacity, they could encounter similar challenges in the future.
Don't Miss:
<ul>
<li>Investing in real estate just got a whole lot simpler. This <a href="https://www.benzinga.com/go/bezos-landlord">Jeff Bezos-backed startup will allow you to become a landlord</a> in just 10 minutes, and you only need $100.</li>
<li>Want To Grow Your Wealth Passively? Unlock Real Wealth with <a href="https://www.benzinga.com/money/cityfunds-yield">Cityfunds&#8217; Exclusive 8% Yield Fund</a>.</li>
</ul>
States that are starting to experience the same issues include Nevada, which generates 23% of its power from solar, and Hawaii, which has thousands of homes with rooftop solar.
In April 2024, the Biden administration launched a program to create or expand solar programs in low-income and disadvantaged communities.
"Today, my administration is investing $7 billion in a new program called Solar for All that will enable over 900,000 low-income households to have solar on their rooftops for the first time," Biden posted on X on April 22. "Solar for All will give folks more breathing room — and cleaner breathing room at that."
Trending:
<ul>
<li>Elon Musk Is Bullish On Austin. Here&#8217;s <a href="https://www.benzinga.com/go/musk-austin">How To Invest In The City&#8217;s Growth Before He Floods It With New Tech Workers</a>.</li>
</ul>
California is one of the states in line to receive a $250 million grant from the Solar for All program to expand residential solar in low-income and disadvantaged communities.
Not everyone shares Biden's enthusiasm for the program. Jessica "Elle" Smith criticized the use of public money for the program, writing, "Translation: ‘I'm blowing $7 billion of your money equipping 900,000 of the most likely to default single-family homes with solar, so when BlackRock sweeps them up in foreclosure, they won't have to do it themselves."
John Podesta, senior adviser to the president for international climate policy, said the program will ensure low-income communities and not just well-off communities will benefit from cost savings that the Solar for All program provides.
"Solar is the cheapest form of electricity — and one of the best ways to lower energy costs for American families," Podesta said at the time the program was announced.
Read Next:
<ul>
<li>Dara Khosrowshahi-Backed Startup Lets You <a href="https://www.benzinga.com/go/dara-backed-startup">Become a Landlord with $100</a>.</li>
<li>Miami Is Expected To Take New York's Place As The US Financial Capital. <a href="https://www.benzinga.com/go/miami-financial-capital">Invest In It With $500 Before That Happens</a>.</li>
</ul>

Real Estate

Shining Too Bright: California's Solar Success Sparks Price Plunge

Wedbush analyst Nick Setyan maintains McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) with a Outperform and lowers the price target from $330 to $300.

Wedbush Maintains Outperform on McDonald's, Lowers Price Target to $300

Morgan Stanley analyst Toni Kaplan maintains TransUnion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRU#NYSE">TRU</a>) with a Overweight and raises the price target from $87 to $90.

Morgan Stanley Maintains Overweight on TransUnion, Raises Price Target to $90

HOV, LTRX and ELDN among mid-day movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start the day with a breakdown of the biggest pre-market stock movers for Thursday morning!
Moving stocks are sales, earnings reports, a spin-off, and more.
Let&rsquo;s get into this news below!

<h2>Pre-Market Stock Movers: 10 Top Gainers</h2>
<ol>
<li>T2 Biosystems (NASDAQ:<a href="https://investorplace.com/stock-quotes/ttoo-stock-quote/">TTOO</a>) stock is rocketing 50% after announcing <a href="https://finance.yahoo.com/news/t2-biosystems-announces-second-largest-130000115.html">a major instrument sale</a>.</li>
<li>Airspan Networks (NYSEMKT:<a href="https://investorplace.com/stock-quotes/mimo-stock-quote/">MIMO</a>) shares are soaring more than 37%.</li>
<li>AGBA Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/agba-stock-quote/">AGBA</a>) stock is surging over 32% alongside heavy trading.</li>
<li>Fortress Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/fbio-stock-quote/">FBIO</a>) shares are rising more than 31% despite a lack of news on Thursday morning.</li>
<li>QuantaSing (NASDAQ:<a href="https://investorplace.com/stock-quotes/qsg-stock-quote/">QSG</a>) stock is increasing 25% after releasing <a href="https://www.nasdaq.com/press-release/quantasing-announces-unaudited-financial-results-for-the-third-quarter-of-fiscal-year">financial results for fiscal Q3 2023</a>.</li>
<li>SenesTech (NASDAQ:<a href="https://investorplace.com/stock-quotes/snes-stock-quote/">SNES</a>) shares are gaining over 21% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317535103&amp;type=PDF&amp;symbol=SNES&amp;cdn=ef6559b2f4e971c5a51470b2cd90a167&amp;companyName=SenesTech+Inc.&amp;formType=4%2FA&amp;formDescription=%5BAmend%5D+Statement+of+changes+in+beneficial+ownership+of+securities&amp;dateFiled=2023-05-31">alongside insider buying</a>.</li>
<li>Hoth Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/hoth-stock-quote/">HOTH</a>) stock is climbing more than 20% <a href="https://thefly.com/permalinks/entry.php/id3724367/HOTH-Hoth-Therapeutics-assumed-with-a-Buy-at-EF-Hutton">after getting a new buy rating</a>.</li>
<li>Chewy (NYSE:<a href="https://investorplace.com/stock-quotes/chwy-stock-quote/">CHWY</a>) shares are jumping over 18% with a <a href="https://www.cnbc.com/2023/05/31/chewy-chwy-q1earnings-report-2023.html">Q1 earnings beat</a>.</li>
<li>Bone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/">BBLG</a>) stock is getting a more than 18% boost without any news this morning.</li>
<li>AC Immune (NASDAQ:<a href="https://investorplace.com/stock-quotes/aciu-stock-quote/">ACIU</a>) shares are up close to 18% today.</li>
</ol>

<h2>10 Top Losers</h2>
<ol>
<li>ClearOne (NASDAQ:<a href="https://investorplace.com/stock-quotes/clro-stock-quote/">CLRO</a>) stock is crashing over 42% without any apparent news this morning.</li>
<li>MDU Resources (NYSE:<a href="https://investorplace.com/stock-quotes/mdu-stock-quote/">MDU</a>) shares are plummeting more than 30% as it prepares to <a href="https://www.nasdaq.com/press-release/knife-river-set-to-join-sp-midcap-400-bank-of-hawaii-to-join-sp-smallcap-600-2023-05">spin off Knife River</a>.</li>
<li>Aridis Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/ards-stock-quote/">ARDS</a>) stock is diving over 21% following a massive rally yesterday.</li>
<li>C3.ai (NYSE:<a href="https://investorplace.com/stock-quotes/ai-stock-quote/">AI</a>) shares are taking a nearly 21% beating despite <a href="https://finance.yahoo.com/news/c3ai-stock-plummets-after-q1-earnings-beat-expectations-210159080.html">beating Q1 earnings estimates</a>.</li>
<li>Okta (NASDAQ:<a href="https://investorplace.com/stock-quotes/okta-stock-quote/">OKTA</a>) stock is falling around 20% after <a href="https://finance.yahoo.com/news/okta-announces-first-quarter-fiscal-200100165.html">releasing its latest earnings report</a>.</li>
<li>Eledon Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/eldn-stock-quote/">ELDN</a>) shares are sliding more than 17% on Thursday.</li>
<li>VolitionRX (NYSEMKT:<a href="https://investorplace.com/stock-quotes/vnrx-stock-quote/">VNRX</a>) stock is dropping over 16% after <a href="https://finance.yahoo.com/news/volitionrx-limited-announces-proposed-underwritten-200100259.html">proposing a public stock offering</a>.</li>
<li>QualTek Services (NASDAQ:<a href="https://investorplace.com/stock-quotes/qtek-stock-quote/">QTEK</a>) shares are decreasing more than 16% <a href="https://investorplace.com/2023/05/why-is-qualtek-services-qtek-stock-up-188-today/">after rallying yesterday</a>.</li>
<li>Lexicon Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/lxrx-stock-quote/">LXRX</a>) stock is slipping over 15% alongside <a href="https://www.benzinga.com/pressreleases/23/05/g32657073/lexicon-announces-proposed-public-offering-of-common-stock">a proposed stock offering</a>.</li>
<li>Victoria&rsquo;s Secret (NYSE:<a href="https://investorplace.com/stock-quotes/vsco-stock-quote/">VSCO</a>) shares close out our pre-market stock movers down more than 14% with the release of its <a href="https://www.victoriassecretandco.com/news-releases/news-release-details/victorias-secret-co-reports-first-quarter-2023-results">most recent earnings report</a>.</li>
</ol>
On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
<ul>
<li>
						<a href="https://investorplace.com/2022/07/little-known-apple-project/?cid=MKT639809&amp;eid=MKT653131">Buy This $5 Stock BEFORE This Apple Project Goes Live</a>
					</li>
<li>
						<a href="https://investorplace.com/2022/06/this-could-be-the-best-deal-in-the-history-of-independent-investing-research/?cid=MKT638063&amp;eid=MKT644740">The Best $1 Investment You Can Make Today</a>
					</li>
<li>
						<a href="https://investorplace.com/2023/04/one-of-the-worlds-biggest-tech-breakthroughs-could-be-happening-in-americas-heartland/?cid=MKT714907&amp;eid=MKT731269">Wall Street Titan: Here&rsquo;s My #1 Stock for 2023</a>
					</li>
<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT513141">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
</ul>
<div>
<div>
<div></div>
<div></div>
</div>
</div>
The post <a href="https://investorplace.com/2023/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-june-1st/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start off trading for Tuesday with a breakdown of the biggest pre-market stock movers this morning.
Moving stocks are clinical trial updates, earnings reports, a public stock offering, and more.
Let&rsquo;s get into that news down below!

<h2>Pre-Market Stock Movers: 10 Top Gainers</h2>
<ol>
<li>Biophytis (NASDAQ:<a href="https://investorplace.com/stock-quotes/bpts-stock-quote/">BPTS</a>) stock is rocketing more than 44% after <a href="https://www.nasdaq.com/press-release/biophytis-and-seqens-sign-a-partnership-to-produce-sarconeos-bio101-active-compound">signing a production partnership</a> for Sarconeos.</li>
<li>Karyopharm Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kpti-stock-quote/">KPTI</a>) shares are soaring over 23% after getting <a href="https://www.nasdaq.com/press-release/karyopharm-receives-fda-fast-track-designation-for-selinexor-for-the-treatment-of">fast-track designation</a> for its myelofibrosis treatments.</li>
<li>Scilex (NASDAQ:<a href="https://investorplace.com/stock-quotes/sclx-stock-quote/">SCLX</a>) stock is surging more than 20% without any clear news this morning.</li>
<li>NextNav (NASDAQ:<a href="https://investorplace.com/stock-quotes/nn-stock-quote/">NN</a>) shares are gaining over 19% on Tuesday morning.</li>
<li>Rubicon Technologies (NYSE:<a href="https://investorplace.com/stock-quotes/rbt-stock-quote/">RBT</a>) stock is increasing close to 18% alongside heavy trading this morning.</li>
<li>Aridis Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/ards-stock-quote/">ARDS</a>) shares are rising more than 16% after getting an agreement for <a href="https://www.nasdaq.com/press-release/aridis-receives-agreement-from-the-european-medicines-agency-ema-on-the-clinical">a Phase 3 clinical trial</a>.</li>
<li>Sunworks (NASDAQ:<a href="https://investorplace.com/stock-quotes/sunw-stock-quote/">SUNW</a>) stock is climbing over 16% on Tuesday morning.</li>
<li>Healthcare Triangle (NASDAQ:<a href="https://investorplace.com/stock-quotes/hcti-stock-quote/">HCTI</a>) shares are getting a more than 13% boost today.</li>
<li>Advent Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/adn-stock-quote/">ADN</a>) stock is jumping almost 13% this morning.</li>
<li>iSun (NASDAQ:<a href="https://investorplace.com/stock-quotes/isun-stock-quote/">ISUN</a>) shares are up nearly 13% on Tuesday morning.</li>
</ol>

<h2>10 Top Losers</h2>
<ol>
<li>9 Meters Biopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/nmtr-stock-quote/">NMTR</a>) stock is plummeting 55% without any apparent news this morning.</li>
<li>Dynatronics (NASDAQ:<a href="https://investorplace.com/stock-quotes/dynt-stock-quote/">DYNT</a>) shares are diving over 28% on Tuesday morning.</li>
<li>Masimo (NASDAQ:<a href="https://investorplace.com/stock-quotes/masi-stock-quote/">MASI</a>) stock is tumbling more than 27% <a href="https://www.businesswire.com/news/home/20230717088647/en/Masimo-Announces-Preliminary-Second-Quarter-2023-Revenue-Results">alongside its preliminary earnings report</a>.</li>
<li>CEL-SCI (NYSEMKT:<a href="https://investorplace.com/stock-quotes/cvm-stock-quote/">CVM</a>) shares are taking an over 24% beating after <a href="https://www.nasdaq.com/press-release/cel-sci-announces-pricing-of-public-offering-2023-07-17">announcing a public offering</a>.</li>
<li>ProMIS Neurosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/pmn-stock-quote/">PMN</a>) stock is dropping close to 17% on Tuesday morning.</li>
<li>First Wave BioPharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/fwbi-stock-quote/">FWBI</a>) shares are sliding more than 13% as it continues recent negative movement.</li>
<li>Lixte Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/lixt-stock-quote/">LIXT</a>) stock is decreasing almost 12% <a href="https://www.nasdaq.com/press-release/preclinical-results-of-lixte-biotechnologys-collaboration-with-netherlands-cancer">following a rally on Tuesday</a>.</li>
<li>TC BioPharm (NASDAQ <a href="https://investorplace.com/stock-quotes/tcbp-stock-quote/">TCBP</a>) shares are slipping over 11% on Tuesday.</li>
<li>Hub Cyber Security (NASDAQ:<a href="https://investorplace.com/stock-quotes/hubc-stock-quote/">HUBC</a>) stock is dipping 11% today.</li>
<li>Baosheng Media (NASDAQ:<a href="https://investorplace.com/stock-quotes/baos-stock-quote/">BAOS</a>) shares close out our pre-market stock movers down nearly 10%.</li>
</ol>
On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
<ul>
<li>
						<a href="https://investorplace.com/2022/07/little-known-apple-project/?cid=MKT639809&amp;eid=MKT739310">Buy This $5 Stock BEFORE This Apple Project Goes Live</a>
					</li>
<li>
						<a href="https://investorplace.com/2023/04/one-of-the-worlds-biggest-tech-breakthroughs-could-be-happening-in-americas-heartland/?cid=MKT714907&amp;eid=MKT739331">Wall Street Titan: Here&rsquo;s My #1 Stock for 2023</a>
					</li>
<li>
						<a href="https://investorplace.com/2022/06/this-could-be-the-best-deal-in-the-history-of-independent-investing-research/?cid=MKT638063&amp;eid=MKT739342">The $1 Investment You MUST Take Advantage of Right Now</a>
					</li>
<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT739347">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
</ul>
<div>
<div>
<div></div>
<div></div>
</div>
</div>
The post <a href="https://investorplace.com/2023/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-july-18th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Aridis pharmaceuticals announces $2 million offering to fund working capital needs

Vernon Bernardino, an analyst from H.C. Wainwright, reiterated the Buy rating on Aridis Pharmaceuticals (ARDS – Research Report). The associated pr...

FDA's Qualified Infectious Disease Product Designation Bolsters Aridis Pharmaceuticals' Investment Appeal: An Analyst's Buy Recommendation

Aridis Pharmaceuticals GAAP EPS of $0.00 beats by $0.10, revenue of $0.42M misses by $1.08M

Promising Developments and Value Proposition: A Buy Rating Analysis of Aridis Pharmaceuticals

ACIU

AGBA

BAOS

BBLG

BHAT

CHWY

CLRO

DYNT

EEIQ

ELDN

FBIO

HOTH

HUBC

IDAI

LAES

LNSR

LTRX

LXRX

MIMO

NEPH

NTRB

OKTA

QTEK

SCLX

SNES

SUNW

TTOO

VNRX

VSCO

WLGS

Press Releases

Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update

Aridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)

Aridis Pharmaceuticals and Rail Vision Interviews to Air on Bloomberg TV on the RedChip Money Report(R)

Aridis' AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA's Qualified Infectious Diseases Product (QIDP) Designation

Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301

Aridis Pharmaceuticals Announces $2 Million Offering

Aridis Pharmaceuticals, Inc., Genetic Technologies Limited, and American Resources Corporation Interviews to Air on the RedChip Money Report® on Bloomberg TV

Penny Stocks On The Move (ATVK, IQST, ENZC, ARDS)

Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update